PARIS – (BUSINESS WIRE) – January 10, 2022–
TISSIUM, a privately held medical technology company developing programmable biomorphic polymers for tissue reconstruction, today announced that it has appointed Ruth Krestin as Vice President of Portfolio Strategy at TISSIUM. In this role, she will be responsible for coordinating TISSIUM’s vertical markets and driving an effective strategy at the portfolio level.
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/2020110005446/en/
Ruth Krestin (Photo: TISSIUM)
Ms. Krestin joins TISSIUM with extensive experience of over 10 years of experience in the pharmaceutical industry. She comes from AstraZeneca, where she held various strategic leadership positions spanning R&D and sales organizations. More recently, she was Director of Competitive Intelligence, CVRM. His main expertise includes R&D operations, competitive intelligence, portfolio management and data analysis.
Prior to AstraZeneca, she spent 5 years in consulting at PwC and as a result brings strategy consulting methodologies and strong analytical skills to her new role at TISSIUM.
Ms. Krestin’s addition to TISSIUM’s leadership team is the latest in a series of senior executive appointments as TISSIUM continues to expand its platform and prepare for commercialization. With a full executive suite spanning its operations across Europe and the United States, TISSIUM is well-staffed to support the expansion it anticipates over the next few years.
Christophe Bancel, CEO of TISSIUM, said: “We are delighted that Ruth is joining the team as we continue to advance and grow the business. His solid background in consulting and quantification along with his extensive experience in sales and R&D functions will bring cross-functional alignment within the company and help us develop our various verticals as we move forward. We are confident that his expertise will allow him to significantly contribute to the advancement of our platform as we remain focused on our goal of transforming tissue repair.
Ms. Krestin said: “I am honored to join TISSIUM in this important new role. TISSIUM has made incredible progress with its unique biopolymer platform and I look forward to assisting in the development and commercialization of its product pipeline.
TISSIUM, a private medical technology company based in Paris, France and Boston, United States, is dedicated to the development and commercialization of products derived from its unique biopolymer platform. The company’s products will address many unmet clinical needs, including the repair and reconstruction of atraumatic tissue.
TISSIUM is developing a portfolio of products that take advantage of its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which form the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products in three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to improve the process of tissue reconstruction in a unique way. In addition, the company is developing additional delivery and activation devices to improve the performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more For more information, please visit: www.TISSIUM.com and @TISSIUMtech.
See the source version on businesswire.com: https://www.businesswire.com/news/home/2020110005446/en/
CONTACT: Investor relations
Romain Attard – Chief Financial Officer
Phone: +33 1 76 21 72 28
Phone. : +1 646-770-8858 Yoann Besse
Phone: +33 6 63 03 84 91
KEYWORD: FRANCE EUROPE
INDUSTRY KEYWORD: CARDIOLOGY SCIENCE OTHERS SCIENCE BIOTECHNOLOGY SURGERY HEALTH MEDICAL DEVICES OTHERS HEALTH
Copyright Business Wire 2022.
PUB: 01/10/2022 05:08 AM / DISC: 01/10/2022 05:08 AM